Benchmark initiated coverage on Scopus BioPharma
$SCPS
Biotechnology: Pharmaceutical Preparations
Health Care
Benchmark initiated coverage of Scopus BioPharma with a rating of Buy
Save time and jump to the most important pieces.
NEW YORK, May 05, 2022 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: "SCPS"), a biopharmaceutical company developing transformational therapeutics for serious diseases with significant unmet medical need, today announced the appointment of Raphael ("Rafi") Hofstein, Ph.D. to its Board of Directors ("Board"). Joshua R. Lamstein, Chairman of Scopus BioPharma, stated, "We are thrilled Dr. Hofstein is rejoining our Board. Dr. Hofstein brings invaluable insights and unparalleled experience in building start-up biotechnology companies into industry leaders." Dr. Hofstein is a global leader in the biopharmaceutical and biotechnology industries. Over his career, Dr. Hofstein has been in
Overwhelming Majority of Shares Voted by Unaffiliated Stockholderswere in Favor of Scopus' Director Nominees Lasters' Ownership Position and Annual Meeting Results are being Challenged in Court Company Believes Ultimate Outcome of Annual Meeting Will Depend on Results of Pending Cases NEW YORK, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (NASDAQ:SCPS) ("Scopus" or the "Company") today announced that it has filed an amendment to the Current Report on Form 8-K that was filed by the Company on December 27, 2021 with the U.S. Securities and Exchange Commission disclosing the certified voting results of the Annual Meeting of Stockholders (the "Annual Meeting"). In addition, Scop
NEW YORK and JERUSALEM, Jan. 6, 2022 /PRNewswire/ -- Dr. Morris C. Laster ("Dr. Laster"), who, together with other proxy participants, beneficially owns 6,006,000 shares of common stock, par value $0.001, of Scopus BioPharma Inc. (NASDAQ:SCPS) ("Scopus" or the "Company"), announced today that stockholders of the Company have elected Dr. Laster's two director nominees, Mordechai Saar Hacham and Joshua Levine to the Company's Board of Directors at the Company's 2021 Annual Meeting of Stockholders (the "Annual Meeting"). First Coast Results, Inc., the independent inspector of elections appointed by the Company for the Annual Meeting, today certified the final results of the election reporting t
Transaction Creates Global Leader in Oligonucleotide Cancer Therapeutics Combined Assets Target Broad Range of Hematological Malignancies and Solid Tumors NEW YORK, June 30, 2021 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: "SCPS"), a clinical-stage biopharmaceutical company developing transformational therapeutics, today announced the acquisition of Los Angeles-based Olimmune Inc. Olimmune is a developer of groundbreaking oligonucleotide immunotherapies for treatment-resistant and metastatic cancers. Olimmune's lead drug candidate, OLIM-01, is being developed for genitourinary and head and neck cancers. It is anticipated that INDs for these indications will be submitt
SC 13D - Scopus BioPharma Inc. (0001772028) (Subject)
SC 13D/A - Scopus BioPharma Inc. (0001772028) (Subject)
SC 13D/A - Scopus BioPharma Inc. (0001772028) (Subject)
Gainers Jasper Therapeutics (NASDAQ:JSPR) shares moved upwards by 576.1% to $3.27 during Tuesday's regular session. As of 12:30 EST, this security is trading at a volume of 39.7 million shares, making up 55465.5% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $121.0 million. Lucira Health (NASDAQ:LHDX) stock increased by 512.33% to $0.68. Trading volume for Lucira Health's stock is 119.7 million as of 12:30 EST. This is 35583.0% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $27.6 million. Reshape Lifesciences (NASDAQ:RSLS) shares moved upwards by 96.73% to $13.26. The cur
Gainers Dermata Therapeutics (NASDAQ:DRMA) shares increased by 101.8% to $0.4 during Monday's regular session. As of 12:30 EST, this security is trading at a volume of 44.7 million shares, making up 5373.9% of its average full-day volume over the last 100 days. The company's market cap stands at $4.8 million. 180 Life Sciences (NASDAQ:ATNF) shares rose 79.36% to $3.39. Trading volume for this security as of 12:30 EST is 39.5 million, which is 2695.3% of its average full-day volume over the last 100 days. The company's market cap stands at $12.6 million. Palisade Bio (NASDAQ:PALI) stock increased by 61.46% to $5.2. Trading volume for this security as of 12:30 EST is 89.4 million, which is
Gainers Hoth Therapeutics (NASDAQ:HOTH) shares moved upwards by 143.4% to $10.71 during Thursday's regular session. As of 12:30 EST, this security is trading at a volume of 20.7 million shares, making up 17470.8% of its average full-day volume over the last 100 days. The company's market cap stands at $13.9 million. Quotient (NASDAQ:QTNT) shares increased by 93.95% to $0.45. Trading volume for Quotient's stock is 38.6 million as of 12:30 EST. This is 4861.7% of its average full-day volume over the last 100 days. The company's market cap stands at $1.5 million. Palisade Bio (NASDAQ:PALI) shares moved upwards by 53.59% to $2.78. The current volume of 6.2 million shares is 466.2% of Palisade
1-Z - Scopus BioPharma Inc. (0001772028) (Filer)
15-12G - Scopus BioPharma Inc. (0001772028) (Filer)
8-K - Scopus BioPharma Inc. (0001772028) (Filer)
Benchmark initiated coverage of Scopus BioPharma with a rating of Buy and set a new price target of $20.00
The Benchmark Company initiated coverage of Scopus BioPharma with a rating of Speculative Buy and set a new price target of $20.00
Benchmark initiated coverage of Scopus BioPharma with a rating of Buy
DUET-102 in Combination with PD-1 Blockade Demonstrates Significant Anti-Tumor Activity in Models of Malignant Glioma Data Suggests Benefits of Combinations of DUET-102 with Other T-Cell Based Immunotherapies, such as CAR-Ts NEW YORK, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (OTCQB: "SCPS") and its majority-owned subsidiary, Duet BioTherapeutics Inc., presented compelling new data that DUET-102 in combination with PD-1 blockade demonstrates significant anti-tumor activity in models of malignant glioma. The new data was presented on November 4, 2023 at the 38th Annual Meeting of the Society for Immunotherapy of Cancer ("SITC") by Marcin Kortylewski, Ph.D. Dr. Kortylewski,
NEW YORK, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (OTCQB: "SCPS"), a biotechnology company developing transformational therapeutics for serious diseases with significant unmet medical need, and its subsidiary, Duet BioTherapeutics Inc., which is developing novel immunotherapies to overcome treatment-resistant cancers, today announced that Marcin Kortylewski, Ph.D., Co-Founder and Senior Scientific Advisor of Duet and Professor of Immuno-Oncology at City of Hope, will be presenting at the 38th Annual Meeting of the Society for Immunotherapy of Cancer ("SITC"). SITC is being held from November 3-5, 2023, in San Diego, California. Details of the presentation are as follows:
NEW YORK, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: "SCPS"), a biopharmaceutical company developing transformational therapeutics for serious diseases with significant unmet medical need, and its pure-play immuno-oncology subsidiary, Duet BioTherapeutics, today announced that key scientific data will be will be presented at the 37th Annual Meeting and Exposition of the Society for Immunotherapy of Cancer ("SITC"). SITC is being held from November 8-12, 2022 at the Boston Convention and Exhibition Center in Boston, Massachusetts. About Scopus BioPharma Scopus BioPharma Inc. is a biopharmaceutical company developing transformational therapeutics for serious diseases
4 - Scopus BioPharma Inc. (0001772028) (Issuer)
4 - Scopus BioPharma Inc. (0001772028) (Issuer)
4 - Scopus BioPharma Inc. (0001772028) (Issuer)